In the above article [Jessen M, Frederiksen K, Yi F, Clausen RP, Hansen KB, Bräuner-Osborne H, Kilburn P, and Damholt A (2017) Mol. Pharmacol 92(2): 151-161; doi: https://doi.org/10.1124/mol.117.108944 ], the authors discovered a few errors along with panels B in Figure 2 and 4 are incorrect. The x-axis for GluN1/2C in Figure 2B is a factor 10 too low. The highest concentration tested was 1000 nM and not 100 nM. In figure 4B, the concentration for GluN1/2D should have been shown as µM (the same as for GluN1/2A, GluN1/2B, and GluN1/2C) and not as nM. The following errors and Figure 2 and 4 have been corrected as displayed below and in the PDF and HTML versions of this article. The authors regret these errors and any inconvenience they may have caused.
Legend to Figure 2A: “10 AICP” should be “10 µM AICP”.
Legend to Figure 2B: “subtypes in in the presence” should be “subtypes in the presence”.
Page 154: It is stated that EC50 values of DCS are 110- to 570-fold higher (i.e., lower potencies) than the corresponding EC50 values of AICP. This is incorrect and should be 120- to 2600-fold higher.
Page 155: “mutations in GluN1 (F484L + T518L)” should be “mutations in GluN1 (F484A + T518L)”.
Page 155: It is stated that the potency of AICP was dramatically reduced (130- to 10,000-fold) at mutant GluN1/2A and GluN1/2C receptors compared with the respective wild-type receptors. This is incorrect and should be 140- to 10,000-fold reduced.
Legend to Figure 6D: “τdeactivationn” should be “τdeactivation”.
Legend to Figure 7: “mean ± S.E.M.” should be “mean ± S.D.”.
Page 160: It is stated that the GluN2 ATD could influence the interface between GluN1 and GluN2 agonist binding domains and thereby prohibit or enable interactions formed by Gln800 in GluN2B and Glu790 in GluN2C. This is incorrect and should be Gln800 in GluN2C and Glu790 in GluN2B.
- Copyright © 2018 The American Society for Pharmacology and Experimental Therapeutics
